Role of plasminogen activators and matrix metalloproteinases in matrix degradation

Roger Lijnen; Peter Carmeliet; D Collen

Related publications

Article1999

Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure

Stéphane Heymans, Aernout Luttun, Dieter Nuyens, Gregor Theilmeier, Esther E. Creemers, Lieve Moons, G.D. Dyspersin, Jack P.M. Cleutjens, M. Shipley, Anne Angellilo, Moshe Levi, O. Nüβe, Andrew H. Baker, Eli Keshet, Florea Lupu, J‐M. Herbert, Jos F.M. Smits, Steven D. Shapiro, Myriam Baes, M. Borgers, D Collen, Mat J.A.P. Daemen, Peter Carmeliet

Article1997

Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic Glomerulonephritis

A. Richard Kitching, Stephen R. Holdsworth, Victoria A. Ploplis, Edward F. Plow, Désiré Collen, Peter Carmeliet, Peter G. Tipping

Article2006

Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis

Stéphane Heymans, Matthias Pauschinger, Armando De Palma, Angela Kallwellis-Opara, Susanne Rutschow, Melissa Swinnen, Davy Vanhoutte, Fangye Gao, Raimund Torpai, Andrew H. Baker, Elisabeth Padalko, Johan Neyts, Heinz‐Peter Schultheiß, Frans Van de Werf, Peter Carmeliet, Yigal M. Pinto

Article2004

Matrix Metalloproteinases and Their Clinical Applications in Orthopaedics

Diah S. Bramono, John C. Richmond, Paul P. Weitzel, David Kaplan, Gregory H. Altman

Letter2011

Matrix Metalloproteinases and Bullae in Pediatric Henoch Schönlein Purpura

Se Jin Park, Ji Hong Kim, Tae Sun Ha, Jae Il Shin